Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
fWnRcemBXfq3e73d
